Skip to main content
. 2015 Jun 24;20(7):11660–11675. doi: 10.3390/molecules200711660

Figure 2.

Figure 2

The changes of SOD (a) and POD (b) activities (The data presented are the mean ± SD). T1: Xoo + Compound 2-(methyl sulfonyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole; T2: Xoo + Bismerthiazol; T3: Xoo; T4: Untreated blank control.